△COMPANIESCompanies rated · 435 (no change)△PROJECTSProjects rated · 70 (no change)△CATALOGUE874 grants in catalogue · 19 open right now•POWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CA△COMPANIESCompanies rated · 435 (no change)△PROJECTSProjects rated · 70 (no change)△CATALOGUE874 grants in catalogue · 19 open right now•POWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CA
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Concepts
CaAKG-based epigenetic age reduction
Primary
Ponce de Leon Health's Rejuvant is positioned as an alpha-ketoglutarate-based, non-drug formulation that should affect human aging by reducing biological age as measured by DNA methylation clocks. The causal claim is that sustained use of the CaAKG-based formulation can shift methylation-based aging biomarkers toward a younger profile, which is treated as evidence of delayed or partially reversed biological aging.
Testable predictions are that users receiving Rejuvant will show lower DNA methylation age after months of use, that effects will be detectable over baseline within individuals, and that older chronological or biological-age groups may show larger benefit.
The premise is biologically plausible in a narrow sense: alpha-ketoglutarate sits inside core metabolism, and DNA methylation clocks can move after interventions. The weak link is the jump from a methylation-clock shift to delayed or partially reversed human aging. That surrogate claim is still unsettled. A younger clock readout is a signal worth testing, but it is not the same as fewer fractures, lower mortality, better immune function, or slower clinical decline.
Supporting evidence: Rejuvant is described as an alpha-ketoglutarate-based formulation intended to affect DNA methylation age biomarkers.; The cited retrospective analysis reported an average DNA methylation biological-age decrease of about 8 years after an average of 7 months of use.; The theory makes a coherent biomarker-level causal claim: sustained CaAKG-based use should shift methylation age toward a younger profile.
Counter evidence: The evidence context treats DNA methylation clocks as surrogate outcomes for biological aging, but that assumption has only medium confidence.; The formulation is non-drug and multi-component, so the mechanistic contribution of CaAKG itself is not isolated here.; The theory does not show that methylation-age reduction caused functional healthspan or lifespan benefit.
Explanatory power3.0
The theory explains the reported before-after methylation shift, but it does not yet beat simpler explanations. The central human evidence is a retrospective 42-person analysis without placebo control. That design leaves regression to the mean, selection bias, lifestyle changes, assay variation, and expectancy-linked behavior on the table. An 8-year average drop is large enough to pay attention to, but the causal attribution is thin.
Supporting evidence: A retrospective analysis of 42 Rejuvant users reported an average DNA methylation biological-age decrease of about 8 years.; The reported decrease occurred in a large majority of participants, which argues against a result driven only by a few extreme responders.; The analysis reported larger benefit among chronologically and biologically older individuals, matching one of the theory's predictions.
Counter evidence: The key attribution assumption, that the methylation-age reduction came from Rejuvant rather than confounding, has low confidence in the evidence graph.; The cited human analysis was retrospective and not placebo-controlled.; The evidence context explicitly says a randomized placebo-controlled trial is required to establish causality more strongly.
Falsifiability8.0
This theory is plainly testable. It predicts lower DNA methylation age after months of use, detectable within-person change from baseline, and possibly larger effects in older biological-age groups. A randomized placebo-controlled trial could prove it wrong if Rejuvant fails to reduce methylation age versus placebo, if the effect disappears after adjustment for baseline age and lifestyle, or if older participants show no larger response.
Supporting evidence: The theory predicts that users receiving Rejuvant for several months will show lower DNA methylation age after use than before use.; It predicts within-individual change between baseline and post-treatment DNA methylation age.; It predicts that chronologically or biologically older users may show larger reductions.
Counter evidence: The age-group prediction is softer than the main biomarker prediction because it is framed as may show larger benefit.; The current evidence does not define a prespecified minimum effect size, clock type, trial duration, or responder threshold needed for success.; Without hard thresholds, sponsors could over-interpret small or clock-specific shifts.
Reasoning tree
premise
Rejuvant is an alpha-ketoglutarate-based, non-drug formulation proposed to affect human aging through changes in DNA methylation age biomarkers.
medium confidence - 1 linked evidence item
assumption
assumes
DNA methylation clocks are valid biomarkers of biological aging and can be used as surrogate outcomes for delayed or partially reversed biological aging.
medium confidence - 1 linked evidence item
derivation
implies
If CaAKG-based Rejuvant shifts DNA methylation age toward a younger profile, this is interpreted as evidence that the intervention reduces biological age.
medium confidence - 1 linked evidence item
prediction
predicts
Users receiving Rejuvant for several months will show lower DNA methylation age after use than before use.
high confidence - 1 linked evidence item
observation
observed_in
A retrospective analysis of 42 individuals taking Rejuvant for an average of 7 months reported an average DNA methylation biological age decrease of about 8 years.
medium confidence - 1 linked evidence item
assumption
requires
The observed DNA methylation age reduction is attributable to Rejuvant rather than placebo effects, regression to the mean, selection bias, lifestyle changes, measurement variation, or other confounders.
low confidence - 1 linked evidence item
assumption
requires
Because the main cited human evidence is retrospective and not placebo-controlled, a randomized placebo-controlled trial is required to establish causality more strongly.
high confidence - 1 linked evidence item
project_implication
implies
If confirmed in controlled trials, CaAKG-based Rejuvant would be a candidate intervention for reducing methylation-defined biological age in humans.
medium confidence - 1 linked evidence item
prediction
predicts
The effect should be detectable within individuals when comparing baseline DNA methylation age to post-treatment DNA methylation age.
high confidence - 1 linked evidence item
observation
observed_in
The reported DNA methylation age decrease was observed in a large majority of participants, suggesting the effect was not driven by only a few individuals.
medium confidence - 1 linked evidence item
prediction
predicts
Chronologically older or biologically older users may show larger reductions in biological age after Rejuvant use.
medium confidence - 1 linked evidence item
observation
observed_in
The retrospective analysis reported additional benefit among chronologically and biologically older individuals.
medium confidence - 1 linked evidence item
Public endorsements
publicly endorses
Kennedy is publicly tied to the product and its core aging claim. Rejuvant names him as Chief Science Officer, and a 2020 Ponce de Leon press release says he would discuss research supporting Rejuvant LifeTabs and its use of genetic markers of aging over time. That is stronger than a passing mention: it is a public commercial and scientific endorsement of the CaAKG epigenetic-age theory behind the product.
Tom Weldon is identified as Ponce De Leon Health's Executive Chairman and Acting CEO, and in his 2022 talk he presents Rejuvant as a supplement to decrease biological age in humans, citing clinical-study data for efficacy. That is a direct public endorsement of the company's CaAKG-based biological-age-reduction theory, not a passing mention.
The provided evidence does not show any public statement from Francis R about Rejuvant, CaAKG, DNA methylation clocks, or epigenetic age reduction. The only record is a PR Newswire company news page, and it does not attribute a view to this person.
silent
The evidence only places Francis R. Palmer, III as Chief Medical Officer at Ponce De Leon Health. It does not show any public statement from him about Rejuvant, CaAKG, DNA methylation clocks, or biological-age reduction. The Rejuvant article excerpt names Oleksandr Demidenko, not Palmer.
mentions
Brian Kennedy is publicly tied to Rejuvant and its aging-biomarker framing, but the dossier does not show a direct statement from him explicitly endorsing the full causal claim that CaAKG lowers DNA methylation age. A Ponce de Leon press release says he would discuss research supporting Rejuvant and says he helped develop the supplement, and the Rejuvant site lists him as Chief Science Officer. That is public association and indirect support, not a clear on-record endorsement of the theory as stated.
CaAKG-based Rejuvant reverses epigenetic biological age
Primary
Ponce de Leon Health's Rejuvant is described as an alpha-ketoglutarate-based formulation intended to delay or reverse biological aging. The causal claim is that supplementation with this natural, non-drug compound formulation can shift DNA methylation patterns measured by biological-age clocks toward a younger state, implying reversal or slowing of biological aging rather than only symptomatic benefit.
A testable prediction is that people taking Rejuvant should show reduced DNA methylation biological age after months of use, with stronger effects potentially in chronologically or biologically older individuals. The provided 2021 retrospective analysis reported an average 8-year decrease in DNA methylation age after about 7 months, while noting that placebo-controlled testing was still required.
The premise is biologically plausible, but only halfway earned. Alpha-ketoglutarate sits inside core metabolism, and DNA methylation clocks can move over months, so the proposed signal is not absurd. The weak link is the jump from a methylation-clock change to reversal of biological aging. That requires the clock shift to track real physiology, not only supplement-related methylation noise or selection effects.
Supporting evidence: Rejuvant is an alpha-ketoglutarate-based formulation proposed to delay, slow, or reverse biological aging in humans.; The theory predicts reduced DNA methylation biological age after several months of use.; The 2021 retrospective analysis reported an average 8-year decrease in DNA methylation age after about 7 months in 42 individuals.
Counter evidence: The key assumption is that DNA methylation biological-age clocks detect meaningful aging changes over months.; The provided human evidence is retrospective, so confounding and measurement effects remain live explanations.; The evidence does not show matched functional aging outcomes, morbidity reduction, or survival benefit.
CaAKG formulation reverses biological age
Primary
Ponce de Leon Health's Rejuvant is theorized to affect aging because its alpha-ketoglutarate-based formulation can reduce biological age as measured by DNA methylation clocks. The causal claim is that sustained use of the CaAKG/vitamin formulation should shift methylation-based aging biomarkers in a younger direction, implying an effect on biological aging rather than only symptomatic health outcomes.
A testable prediction is that people taking Rejuvant for several months should show lower DNA methylation age versus baseline, and ideally versus placebo in a controlled trial. The 2021 Aging paper reports an average 8-year reduction after 4 to 10 months but notes that placebo-controlled testing is still required.
The premise is biologically plausible at the biomarker level: an alpha-ketoglutarate-based formulation could, in principle, alter methylation readouts over months. The weak point is the jump from a younger DNA methylation clock result to reversal of biological aging. That assumes the clock change tracks causal aging biology, and the evidence here does not prove that.
Supporting evidence: Rejuvant is described as an alpha-ketoglutarate-based formulation with vitamins, proposed as a candidate intervention affecting human aging.; The theory makes a specific biomarker claim: sustained use should shift DNA methylation age in a younger direction.
Counter evidence: The theory depends on DNA methylation clocks being valid markers for changes relevant to biological aging, and that assumption is rated medium confidence in the evidence context.; The observed pre-post reduction being caused by Rejuvant rather than confounding is rated low confidence.
Explanatory power3.0
The theory fits the reported 8-year average methylation-age drop, but it does not yet beat simpler explanations. A 42-person retrospective pre-post analysis can be explained by regression to the mean, selection effects, lifestyle changes, assay variation, or other confounders. Without placebo control, the causal claim is doing more work than the data can carry.
Biological aging as upstream cause of degenerative disease
Ponce de Leon Health states that it seeks to reverse the effects of biological aging and moderate aging as a cause of degenerative disease. The causal theory is that aging itself is an upstream driver of multiple degenerative conditions, so a non-drug intervention that slows or reverses biological aging should reduce age-related disease burden and improve healthspan.
Testable predictions are that an effective intervention should change biological-aging biomarkers before or alongside improvements in healthspan-related outcomes, and that benefits should be broader than one disease-specific endpoint.
company website · Wed Jun 24 2026 21:25:11 GMT+0000 (Coordinated Universal Time) · Source
Popperian evaluation
Premise plausibility7.0
The premise is credible: aging biology plausibly sits upstream of many degenerative diseases, and DNA methylation clocks give a practical way to track part of that process in humans. The weak point is causality. A methylation-age change may reflect a causal aging process, a disease-state correlate, a behavior change, assay noise, or regression to the mean. The theory is biologically coherent, but the biomarker cannot carry the whole causal claim by itself.
Supporting evidence: The theory predicts broad age-related disease effects from a shared upstream aging process.; The cited Rejuvant analysis used DNA methylation age as a human aging biomarker when lifespan endpoints were impractical.; The intervention group reportedly showed an average biological-age reduction of about 8 years after roughly 7 months.
Counter evidence: The key human evidence is retrospective and includes only 42 individuals.; The evidence context says placebo-controlled validation is still required.; The biomarker assumption has medium confidence, meaning it may capture correlates of chronological age or health state rather than the causal aging process itself.
Explanatory power5.0
The theory explains why a single intervention might move an aging biomarker and, in principle, affect more than one age-related outcome. It does not yet explain more than the narrow biomarker result. The 8-year methylation-age shift fits the theory, but it also fits simpler explanations: selection bias, lifestyle changes, placebo-associated behavior, measurement variation, or a supplement effect on methylation readouts without clinical benefit. The disease-burden claim remains mostly unpaid.
Anti-inflammatory aging modulation
The Rejuvant Safety and Biomarker Study explicitly tests whether proprietary CaAKG-based dietary supplements have anti-inflammatory properties, using C-reactive protein as the primary endpoint. The causal claim is that the intervention may improve healthspan-relevant aging biology partly by reducing systemic inflammation, a process linked to age-related decline.
Testable predictions are that treated subjects will show reduced C-reactive protein versus placebo, acceptable blood chemistry and adverse-event profiles, and potentially parallel changes in DNA methylation biological age.
The premise is biologically credible at the broad level: systemic inflammation is linked to age-related decline, and C-reactive protein is a standard blood marker for that inflammatory signal. The weaker step is the jump from a CaAKG supplement to healthspan-relevant aging modulation in humans. The current human evidence is a 42-person retrospective DNA methylation analysis after about 7 months, which can raise a hypothesis but cannot carry the causal claim by itself.
Supporting evidence: The proposed study uses C-reactive protein as the primary endpoint for anti-inflammatory activity.; Systemic inflammation is listed as a plausible mechanism connected to age-related decline.; The 2021 Rejuvant analysis reported an average 8-year reduction in DNA methylation biological age after an average of 7 months in 42 users.
Counter evidence: The biological-age evidence is retrospective and lacks the placebo control needed for a causal supplement claim.; The premise assumes DNA methylation age is a valid surrogate for healthspan effects in this intervention context, and that link remains uncertain.; The evidence context gives no direct prior evidence that CaAKG lowers C-reactive protein in humans.
Explanatory power4.0
The theory explains the planned trial logic better than it explains the existing evidence. If C-reactive protein falls versus placebo, the anti-inflammatory mechanism gains real support. But the reported DNA methylation age reduction has several alternative explanations: regression to the mean, selection effects, lifestyle changes, assay variability, or baseline differences. Without randomized inflammatory-marker data, the theory is plausible but underpowered as an explanation.
CaAKG formulation as life- and healthspan intervention
The company frames Rejuvant as a potential life-extending compound formulation built around alpha-ketoglutarate plus vitamins. The proposed causal theory is that this natural-product cocktail can delay or reverse biological aging processes, which in turn should extend healthspan and possibly lifespan, rather than treating a single downstream disease.
Testable predictions are that treated individuals should show improved aging biomarkers, favorable safety and tolerability over repeated use, and downstream evidence consistent with improved healthspan if followed in longer controlled studies.
The premise is biologically plausible in outline: alpha-ketoglutarate sits inside central metabolism, and aging biology can in principle respond to metabolic inputs. The weak point is the leap from a supplement cocktail to delayed or reversed human aging. The theory names the broad target, biological aging, but it does not pin down which pathway must change, which vitamin component matters, or what dose-response pattern would make the causal claim hard to dodge.
Supporting evidence: Rejuvant is described as an alpha-ketoglutarate based formulation with vitamins.; The theory predicts changes in aging biomarkers after repeated use.; The cited 2021 Aging paper reports an average 8-year reduction in DNA methylation biological age after an average of 7 months in 42 users.
Counter evidence: The causal premise depends on DNA methylation age being a meaningful proxy for healthspan or lifespan, which the evidence context treats as an assumption.; The theory does not identify a specific aging mechanism that the formulation must alter.; The available human evidence is retrospective, so baseline health behavior, selection effects, regression to the mean, or test variability could still explain part of the signal.
Explanatory power
Small-molecule age reversal via cellular rejuvenation
Company-linked interview material describes calcium alpha-ketoglutarate and other small molecules as having potential to reverse cellular aging and promote rejuvenation of cells and tissues. For Ponce de Leon Health, the explicit mechanism centers on CaAKG as the critical small molecule in Rejuvant, with effects assessed against other longevity molecules such as NMN, resveratrol, and rapamycin.
A testable prediction is that CaAKG-based Rejuvant should produce measurable improvements in cellular or epigenetic aging markers, and potentially outperform or compare favorably with other candidate longevity molecules in assays of cellular aging reversal.
The premise is biologically plausible at the marker level, but still thin as an age-reversal theory. CaAKG is a defined molecule, Rejuvant is a defined formulation, and DNA methylation age is a measurable endpoint. The weak point is attribution: the evidence names a formulation with alpha-ketoglutarate and vitamins, then treats CaAKG as the critical active agent. That may be true, but the supplied evidence does not isolate CaAKG from the rest of the product.
Supporting evidence: CaAKG is proposed as the critical small molecule in Rejuvant responsible for cellular rejuvenation and age-reversal effects.; A retrospective analysis of 42 individuals taking Rejuvant for an average of 7 months reported an average 8-year reduction in DNA methylation biological age.; The theory predicts measurable changes in cellular or epigenetic aging markers, which are real assay targets rather than vague wellness claims.
Counter evidence: The core human evidence is retrospective, not placebo-controlled.; The supplied evidence does not show that CaAKG alone caused the reported methylation-age change.; The assumption that epigenetic clock movement equals cellular rejuvenation remains only moderately supported here.
CaAKG-based supplementation may improve healthspan through anti-inflammatory effects
The Rejuvant Safety and Biomarker Study frames Ponce de Leon Health's proprietary CaAKG-based dietary supplements as potentially anti-inflammatory. The causal claim is that CaAKG-based supplementation may reduce systemic inflammation, measured by C-reactive protein, and that lowering inflammatory burden is relevant to healthier aging and healthspan.
A testable prediction is that adults receiving the proprietary CaAKG formulation should show improved inflammatory biomarkers, especially reduced C-reactive protein, versus placebo, while maintaining acceptable blood chemistry and adverse-event safety profiles.
The premise is biologically credible in outline: systemic inflammation can be measured with C-reactive protein, and chronic inflammatory burden is plausibly tied to aging biology. The weak part is specificity. The supplied evidence says CaAKG-based supplements are framed as anti-inflammatory, but it does not give a direct mechanism, dose-response data, or human CRP results for the proprietary formulation.
Supporting evidence: The theory names C-reactive protein as the operational inflammatory biomarker.; The causal chain is internally coherent: CaAKG formulation, lower systemic inflammation, lower inflammatory burden, possible healthspan relevance.; The evidence context includes a retrospective Rejuvant analysis reporting an average DNA methylation age decrease after about 7 months of use.
Counter evidence: The main human evidence provided is DNA methylation age, not CRP or another direct inflammatory endpoint.; The anti-inflammatory claim is framed as potential, with no supporting publication attached to the core inflammation premise.; The formulation is proprietary, so CaAKG itself and the full supplement mixture are not cleanly separated.
Explanatory power3.0
The theory does not yet explain the observed evidence strongly. A retrospective 42-person DNA methylation result could fit an anti-inflammatory mechanism, but it could also fit selection bias, regression to the mean, lifestyle changes, assay noise, vitamin co-ingredients, or another non-inflammatory effect of the formulation. Without CRP movement versus placebo, the inflammation explanation is possible, not preferred.
The company's broader theory is that biological aging is a causal driver of degenerative disease, so interventions that moderate, slow, or reverse aging biology should improve healthspan and potentially lifespan. Under this view, aging is not just a correlate of disease risk but an upstream process that can be targeted with safe, affordable, drug-free interventions.
A testable prediction is that a successful non-drug longevity product should improve biomarkers of aging and, over longer follow-up, reduce age-related functional decline or disease burden compared with untreated controls.
company website · Mon Jun 22 2026 23:04:57 GMT+0000 (Coordinated Universal Time) · Source
Popperian evaluation
Premise plausibility6.0
The premise is credible at the broad level: aging biology contributes to degenerative disease risk, and that makes upstream intervention a reasonable hypothesis. The weak point is the jump from that premise to safe, affordable, drug-free products in humans. The evidence supplied supports biomarker movement in 42 people after about 7 months, but it does not show lower disease burden, better function, or longer survival.
Supporting evidence: The theory states a causal claim that biological aging contributes upstream to degenerative disease risk.; The Rejuvant alpha-ketoglutarate formulation study reported an average 8-year reduction in DNA methylation biological age after about 7 months in 42 people.
Counter evidence: The main human evidence is retrospective and lacks a placebo-controlled design.; No supplied evidence shows that biomarker change reduced age-related functional decline or degenerative disease burden.
Explanatory power4.0
The theory can explain why an intervention that shifts aging biomarkers might later affect disease risk, but the supplied evidence has too many live alternatives. Regression to the mean, selection effects, lifestyle changes, assay variability, and placebo-linked behavior changes could all fit the 42-person methylation result. A biomarker drop alone does not force the aging-causality explanation to win.
Small-molecule epigenetic rejuvenation
Company-linked public interviews describe calcium alpha-ketoglutarate and related small molecules as candidates for reversing cellular aging and promoting rejuvenation of cells and tissues through epigenetic reversal. The causal claim is that a non-drug small-molecule intervention can alter aging-associated methylation patterns in a direction consistent with younger cellular state.
A testable prediction is that CaAKG-based supplementation should outperform or compare favorably with other longevity molecules on cellular aging or epigenetic-aging readouts, and should produce measurable methylation-pattern changes associated with biological-age reduction.
The premise is biologically plausible but still underproven. DNA methylation clocks track aging-related molecular state, and a CaAKG formulation was linked to an average 8-year decrease in methylation age after about 7 months in 42 people. The weak link is causality: younger-looking methylation patterns do not automatically mean cells or tissues have been functionally rejuvenated.
Supporting evidence: The theory makes a concrete mechanistic claim: CaAKG and related small molecules can shift aging-associated methylation patterns toward a younger profile.; A retrospective 2021 analysis reported an average DNA methylation age decrease of about 8 years after roughly 7 months of alpha-ketoglutarate-based supplementation.
Counter evidence: The cited human evidence is retrospective, with 42 individuals and no placebo control.; The theory assumes aging-associated methylation patterns are causal markers of cellular aging rather than downstream correlates.
Explanatory power4.0
The theory can explain the reported methylation-age drop, but it does not yet explain it better than ordinary study artifacts. Selection bias, regression to the mean, test variability, behavior changes, and uncontrolled co-interventions all remain live explanations. An 8-year clock shift is large enough to be interesting, but the study design is too loose to make the mechanism carry the weight.
The Rejuvant safety and biomarker program frames proprietary CaAKG-based dietary supplements as having anti-inflammatory properties. The causal theory is that reducing chronic inflammation, measured through biomarkers such as C-reactive protein, may moderate processes linked to aging and age-related decline.
A testable prediction is that adults receiving the CaAKG-based supplement should show favorable changes in inflammatory biomarkers, especially C-reactive protein, while maintaining acceptable safety labs and adverse-event profiles.
The premise is biologically credible at a broad level: chronic inflammation is plausibly tied to aging-related decline, and C-reactive protein can track systemic inflammation in adults. The weak point is specificity. The supplied evidence shows a proprietary alpha-ketoglutarate formulation and a DNA methylation age result, but it does not show that CaAKG lowers C-reactive protein or that inflammation is the main causal path.
Supporting evidence: The theory names a measurable inflammatory biomarker, C-reactive protein, rather than relying only on vague healthspan language.; The reasoning chain states that chronic inflammation contributes causally to aging-related biological processes, a plausible premise in aging biology.
Counter evidence: The cited Rejuvant analysis reports DNA methylation biological age changes in 42 individuals after about 7 months, not direct inflammatory biomarker changes.; The evidence context itself says the retrospective, non-placebo-controlled analysis can support but cannot establish the anti-inflammatory causal mechanism.
Explanatory power3.0
The theory explains little of the observed evidence on its own. An 8-year average decrease in DNA methylation biological age after about 7 months could fit an anti-inflammatory effect, but the evidence does not connect the supplement to lower C-reactive protein, lower chronic inflammation, or clinical healthspan outcomes. Alternative explanations are still sitting in the room: selection bias, regression to the mean, lifestyle changes, assay variation, and placebo-era behavior changes.
There is no public statement here from the named person on the CaAKG and methylation-clock claim. The records mention Ponce de Leon Health and Tom Weldon, and two items repeat company promotional copy about Rejuvant, but none attribute a view to "The News Contact Professional". On this evidence, the person stays silent.
Tom Weldon publicly backs the core claim. He says CaAKG is Rejuvant's main ingredient and that the product is clinically proven, science based, and works. He is also publicly presented as having a much younger biological age, and he is listed as giving a talk titled "DECREASING BIOLOGIC AGE FOR ALL." The missing piece is a direct quote from him about DNA methylation clocks specifically, so this is endorsement of the age-reduction theory in public, with weaker support for the exact biomarker mechanism.
The theory explains the reported clock reduction, but it does not yet explain it better than simpler alternatives. A retrospective before-after result in 42 people can fit several stories: Rejuvant caused a real aging shift, the sample selected for people already changing behavior, the clock varied on repeat testing, or regression to the mean inflated the drop. The 8-year number is large enough to demand a cleaner trial, not large enough to settle causality.
Supporting evidence: The reported average decrease in DNA methylation age matches the theory's main prediction.; The analysis also reported that a large majority of participants decreased biological age.; Older chronological or biological age was reported to associate with additional benefit, matching the theory's secondary prediction.
Counter evidence: The study design was retrospective rather than placebo-controlled.; Placebo-controlled testing was explicitly described as still required.; The evidence context does not rule out lifestyle changes, participant selection, batch effects, or regression to the mean.
Falsifiability8.0
This claim is easy to put at risk. Randomize people to Rejuvant or placebo, pre-specify the DNA methylation clock, run the trial for 4 to 10 months, and ask whether the treatment arm shows a larger age reduction than placebo. A null result, a placebo-matched shift, or a clock change without any linked physiological improvement would damage the aging-reversal claim directly.
Supporting evidence: The theory predicts reduced DNA methylation biological age after months of Rejuvant use.; It predicts stronger effects in chronologically or biologically older individuals.; The existing report gives concrete anchors: 42 individuals, about 7 months of use, and an average 8-year decrease.
Counter evidence: The theory depends heavily on biological-age clocks, so failure modes around clock validity could blur interpretation.; The formulation claim is broader than the current endpoint, because reversing a methylation clock is narrower than reversing biological aging.
Reasoning tree
premise
Rejuvant is an alpha-ketoglutarate-based formulation proposed to delay, slow, or reverse biological aging in humans.
medium confidence - 1 linked evidence item
assumption
assumes
DNA methylation biological-age clocks are valid biomarkers for detecting meaningful changes in biological aging over months.
medium confidence - 1 linked evidence item
premise
assumes
Alpha-ketoglutarate combined with vitamins in Rejuvant is a natural, non-drug compound formulation that could plausibly influence aging biology.
medium confidence - 1 linked evidence item
derivation
implies
If Rejuvant affects aging biology, supplementation should shift DNA methylation patterns measured by biological-age clocks toward a younger state.
medium confidence - 1 linked evidence item
prediction
predicts
People taking Rejuvant for several months should show a reduction in DNA methylation biological age from baseline.
high confidence - 1 linked evidence item
observation
observed_in
A 2021 retrospective analysis of 42 individuals taking Rejuvant for an average of about 7 months reported an average 8-year decrease in DNA methylation age.
medium confidence - 1 linked evidence item
assumption
requires
Because the key human evidence is retrospective, placebo-controlled testing is required before confidently attributing the biological-age reduction to Rejuvant rather than confounding or measurement effects.
high confidence - 1 linked evidence item
project_implication
implies
Rejuvant is an intriguing candidate intervention for human biological aging, but the causal claim remains provisional until confirmed in controlled trials.
high confidence - 1 linked evidence item
observation
observed_in
The same retrospective analysis reported that a large majority of participants decreased biological age after Rejuvant use.
medium confidence - 1 linked evidence item
prediction
predicts
Chronologically or biologically older individuals may show stronger reductions in biological age after Rejuvant supplementation.
medium confidence - 1 linked evidence item
observation
observed_in
The retrospective analysis reported additional benefit among chronologically and biologically older individuals.
Kennedy is publicly tied to Rejuvant at the company level, not just as a distant advisor. Rejuvant's own materials list him as Chief Science Officer, and a Ponce de Leon Health press release says he would speak about research supporting Rejuvant while describing the company as focused on reversal of epigenetic aging. That is public endorsement of the product's aging claim, even though the supplied evidence does not show him personally repeating the full CaAKG and DNA-methylation mechanism in a direct quote.
Tom Weldon is identified as Ponce De Leon Health's Founder, Executive Chairman and Acting CEO, and in his 2022 talk he presents Rejuvant as a supplement designed to decrease biological age in humans, citing clinical-study data on its efficacy. That is a public endorsement of the company's core claim that Rejuvant can shift biological age in a younger direction, not mere neutral mention.
The provided evidence contains no public quote, publication, or attributed statement from Francis R about Rejuvant or the claim that CaAKG reverses epigenetic biological age. The only record is a company press page describing Ponce de Leon Health's positioning, which does not show this person endorsing, mentioning, or contradicting the theory.
The provided evidence only shows Francis R. Palmer, III listed as Chief Medical Officer at Ponce De Leon Health. It does not include any public quote, publication, or statement from him about Rejuvant, alpha-ketoglutarate, or epigenetic age reversal. The Rejuvant record describes the product claim, but it is not attributed to Palmer.
mentions
The record ties Brian Kennedy publicly to Rejuvant, but it does not show him explicitly endorsing the specific claim that CaAKG-based Rejuvant reverses epigenetic biological age. A 2020 PR Newswire release says he would discuss research supporting Rejuvant and that he helped develop the product, and the Rejuvant site lists him as Chief Science Officer. That is stronger than silence, but weaker than a clear public endorsement of the full theory.
The provided evidence does not show any public statement from The News Contact Professional about the claim that CaAKG-based Rejuvant reverses epigenetic biological age. The records mention Ponce de Leon Health and Tom Weldon, but not this person making, endorsing, or disputing the theory.
publicly endorses
Tom Weldon is presented as Rejuvant's founder and is tied to the CaAKG clinical work. Public materials link him to claims that CaAKG is Rejuvant's main ingredient, that the product is clinically proven and works, and that it is discussed in the context of epigenetic and biological age reversal. This is endorsement, not mere mention.
Supporting evidence: The 2021 Aging paper reported an average decrease of about 8 years in DNA methylation biological age after 4 to 10 months of Rejuvant use.; DNAm testing was performed at baseline and after supplementation for an average of about 7 months.
Counter evidence: The analysis was retrospective and included 42 individuals.; The evidence context explicitly names regression to the mean, selection bias, measurement artifacts, lifestyle changes, and other confounders as unresolved alternatives.; Placebo-controlled testing is required to establish causality.
Falsifiability8.0
This theory is easy to put at risk. A randomized placebo-controlled trial can ask whether several months of Rejuvant lowers DNA methylation age versus baseline and versus placebo. If the treatment group fails to separate from placebo, or if clock movement does not repeat across assays, the core claim takes a direct hit.
Supporting evidence: The theory predicts that people taking Rejuvant for several months should show lower DNA methylation age compared with baseline.; It also predicts that, in a controlled trial, people taking Rejuvant should show lower DNA methylation age than a placebo group.
Counter evidence: The theory would be harder to falsify if advocates treat any methylation-clock movement as meaningful without predefining the clock, endpoint, duration, and comparison group.; The current evidence has not yet supplied the placebo-controlled test that would most directly challenge the claim.
Reasoning tree
premise
Ponce de Leon Health's Rejuvant is an alpha-ketoglutarate-based formulation that includes vitamins and is proposed as a candidate intervention affecting human aging.
high confidence - 1 linked evidence item
assumption
assumes
DNA methylation clocks are valid biomarkers for estimating biological age and for detecting changes relevant to biological aging.
medium confidence - 1 linked evidence item
derivation
implies
If Rejuvant reduces DNA methylation age, then sustained use may shift methylation-based aging biomarkers in a younger direction.
medium confidence - 1 linked evidence item
derivation
implies
A younger shift in methylation-based aging biomarkers would support the claim that Rejuvant affects biological aging rather than only symptomatic health outcomes.
medium confidence - 1 linked evidence item
prediction
predicts
People taking Rejuvant for several months should show lower DNA methylation age compared with their own baseline.
high confidence - 1 linked evidence item
observation
observed_in
A retrospective analysis of 42 individuals taking Rejuvant reported DNA methylation testing at baseline and after supplementation for an average of about 7 months.
high confidence - 1 linked evidence item
observation
observed_in
The 2021 Aging paper reported an average decrease of about 8 years in DNA methylation biological age after 4 to 10 months of Rejuvant use.
high confidence - 1 linked evidence item
assumption
assumes
The observed pre-post reduction in DNA methylation age is attributable to Rejuvant rather than regression to the mean, selection bias, measurement artifacts, lifestyle changes, or other confounders.
low confidence - 1 linked evidence item
prediction
predicts
In a controlled trial, people taking Rejuvant should ideally show lower DNA methylation age than a placebo group.
medium confidence - 1 linked evidence item
project_implication
requires
Placebo-controlled testing is required to establish whether Rejuvant causally reduces DNA methylation age.
high confidence - 1 linked evidence item
project_implication
implies
If placebo-controlled trials confirm lower DNA methylation age after Rejuvant use, the formulation would have stronger evidence as an intervention that modifies biological aging biomarkers.
Brian K. Kennedy is publicly presented as Rejuvant/Ponce de Leon Health's Chief Science Officer, and the supplied PR record says he would discuss research supporting Rejuvant and that he helped develop the supplement. That is stronger than a neutral mention and indicates a public endorsement of the product's anti-aging premise, even if it does not independently validate the theory.
Tom Weldon is identified as Ponce de Leon Health's Founder, Executive Chairman, and Acting CEO, and in his 2022 public talk he presents Rejuvant as a supplement developed to decrease biological age in humans, citing clinical-study evidence for its efficacy. That is a direct public endorsement of the theory that the CaAKG-based formulation can reverse biological-age biomarkers.
The provided evidence contains only a general PR Newswire listing about Ponce de Leon Health and does not include any quote, publication, or attributed statement from Francis R addressing the CaAKG/Rejuvant biological-age-reversal theory.
The provided evidence identifies Francis R. Palmer, III as Ponce de Leon Health's Chief Medical Officer, but it includes no public quote, authored publication, interview, or statement from him addressing the CaAKG/Rejuvant biological-age-reversal theory. The supplied Rejuvant publication does not attribute the claim to Palmer.
The public record links Brian Kennedy to Rejuvant and its biological-age positioning: a PR Newswire release says he would discuss research supporting Rejuvant and that he helped develop the supplement, and Rejuvant’s About page lists him as Chief Science Officer. But the provided evidence does not contain a direct public statement from him explicitly endorsing the specific causal claim that the CaAKG formulation reverses biological age.
The provided evidence does not contain a direct public statement, quote, or attributed publication from The News Contact Professional about the CaAKG/Rejuvant biological-age-reversal theory. The records reference Ponce de Leon Health and Tom Weldon, but not this person specifically.
publicly endorses
Public materials tie Tom Weldon directly to Rejuvant’s CaAKG formulation and frame it as effective against biological aging: he is linked to the clinical work behind the product, promotional interview materials say he discusses CaAKG’s role in aging reversal, and company/founder materials say the goal is to reverse biological aging. That is best classified as a public endorsement of the theory rather than mere mention.
Supporting evidence: A broad upstream-aging model predicts changes beyond one disease-specific endpoint.; The reported methylation-age reduction occurred over months, which is consistent with the theory's biomarker-first prediction.
Counter evidence: No multi-endpoint healthspan benefit is provided in the evidence context.; The Rejuvant analysis was retrospective, so alternative explanations remain live.; There is no cited placebo-controlled human trial showing that biomarker change led to lower degenerative disease burden.
Falsifiability8.0
This theory can be tested cleanly. A randomized, placebo-controlled trial could ask whether the intervention changes methylation clocks before or alongside functional outcomes, and whether benefits appear across several age-related measures rather than one cherry-picked endpoint. It would take real discipline to predefine the clocks, endpoints, timing, and failure thresholds. Without those thresholds, the theory risks surviving every null result by switching biomarkers.
Supporting evidence: The theory predicts that effective treatment should change biological-aging biomarkers before or alongside healthspan outcomes.; It predicts benefits across multiple age-related outcomes rather than one disease-specific endpoint.; The evidence context explicitly recommends future validation with both biomarkers and multiple clinical or functional outcomes.
Counter evidence: The current evidence does not define a minimum clinically meaningful biomarker shift.; The theory does not state how many healthspan endpoints must improve, or by how much, for the causal claim to count as supported.; Different aging clocks may disagree, which can make failed predictions easier to explain away after the fact.
Reasoning tree
premise
Biological aging is an upstream causal driver of multiple degenerative and age-related diseases.
medium confidence
assumption
assumes
Biological-aging biomarkers capture a causal aging process rather than only correlates of chronological age or disease state.
medium confidence - 1 linked evidence item
premise
requires
DNA methylation clocks can be used as practical biomarkers to monitor biological age in humans when lifespan outcomes are impractical to measure directly.
medium confidence - 1 linked evidence item
derivation
implies
If aging causally contributes to many degenerative diseases, then slowing or reversing biological aging should reduce broad age-related disease burden.
medium confidence
project_implication
implies
Ponce de Leon Health should prioritize interventions aimed at biological aging itself rather than only disease-specific endpoints.
medium confidence
assumption
assumes
A non-drug intervention can meaningfully slow or reverse biological aging in humans.
medium confidence - 1 linked evidence item
observation
observed_in
A retrospective analysis of 42 individuals taking an alpha-ketoglutarate-based Rejuvant formulation reported an average reduction of about 8 years in DNA methylation biological age after roughly 7 months of use.
medium confidence - 1 linked evidence item
assumption
assumes
The reported biomarker change from Rejuvant use reflects an intervention effect, although placebo-controlled validation is still required.
low confidence - 1 linked evidence item
prediction
predicts
An effective biological-aging intervention should change biological-aging biomarkers before or alongside improvements in healthspan-related outcomes.
high confidence - 1 linked evidence item
project_implication
implies
Future validation should measure both biological-aging biomarkers and multiple healthspan-related clinical or functional outcomes.
high confidence - 1 linked evidence item
prediction
predicts
Benefits from an effective biological-aging intervention should appear across multiple age-related outcomes rather than only one disease-specific endpoint.
Kennedy publicly lines up with the theory. He is named as Chief Science Officer for Rejuvant/Ponce de Leon Health, and the supplied evidence ties him to claims that aging is a shared risk factor across diseases and that rapamycin could point toward an anti-aging drug for people. That is stronger than a passing mention: it is a public role plus public statements consistent with aging as an upstream driver of degenerative disease.
Tom Weldon is identified as Ponce De Leon Health's Founder, Executive Chairman, and Acting CEO, and he publicly gave a 2022 talk titled "Decreasing biological age for all." In that talk summary, he presents Rejuvant as a supplement developed to decrease biological age in humans and cites clinical-study data for efficacy. That is a direct public endorsement of the company's core aging-causation thesis, even if this evidence does not spell out every downstream disease claim in the theory text.
The provided evidence does not contain any public statement from Francis R about this theory. The only record is a PR Newswire page describing Ponce de Leon Health as focused on reversing epigenetic aging, which supports the company's framing, but it does not attribute that view to Francis R personally.
The provided evidence places Francis R. Palmer III at Ponce De Leon Health as Chief Medical Officer, but it does not show any public statement from him about biological aging as an upstream cause of degenerative disease. The Rejuvant record discusses biological aging claims, yet no quote or attributable publication from Palmer is included. On this record, he stays silent.
publicly endorses
Brian Kennedy is presented publicly as Ponce de Leon Health's Chief Science Officer, and a company press release says he helped develop Rejuvant and would speak about supplementation, biological age, healthspan, and longevity. That is a public alignment with the company's aging-first theory, even though the dossier does not include a direct quote from him stating the full causal claim in those exact words.
The dossier gives no public statement from The News Contact Professional about this theory. The records are company listings, reposted news items, and a speaker page for Tom Weldon, not evidence that this founder publicly endorsed, mentioned, or contradicted the claim that biological aging drives degenerative disease.
publicly endorses
Tom Weldon publicly aligns himself with the idea that biological aging can be reduced and that doing so matters for disease. Ponce de Leon Health's public site says it seeks to "reverse the effects of biological aging" and to moderate aging as "the number one cause of degenerative diseases," and Weldon is presented there as the founder. He is also listed for a talk titled "DECREASING BIOLOGIC AGE FOR ALL," and public podcast materials describe him discussing small molecules for "aging reversal" and "epigenetic reversal." That is stronger than a passing mention.
Supporting evidence: The trial directly links the causal claim to a measurable endpoint: reduced C-reactive protein versus placebo.; Parallel DNA methylation changes would fit the idea that inflammation and aging biology move together under treatment.
Counter evidence: The observed DNA methylation age change came from a retrospective 42-person analysis, so it does not rule out non-treatment explanations.; The evidence context does not show that C-reactive protein changed in the earlier Rejuvant users.; Acceptable safety labs and adverse-event profiles would support tolerability, but they would not explain an anti-aging mechanism.
Falsifiability8.0
This is the strongest Popperian dimension. The theory makes a clean, risky prediction: treated subjects should show lower C-reactive protein than placebo. That result can fail. Safety markers and adverse events are also measurable, although they test tolerability more than mechanism. DNA methylation age is weaker because the prediction says it may change, which gives the theory room to survive a null result.
Supporting evidence: The primary endpoint is C-reactive protein, compared between treated subjects and placebo.; The theory predicts acceptable blood chemistry profiles and adverse-event profiles.; The trial can test whether DNA methylation biological age changes in parallel with inflammation.
Counter evidence: The DNA methylation prediction is conditional and soft, so a null result there would be harder to treat as a direct refutation.; The prompt gives no numeric threshold for how much C-reactive protein must fall to count as biologically meaningful.
Reasoning tree
premise
CaAKG-based Rejuvant supplementation is proposed to modulate healthspan-relevant aging biology.
medium confidence - 1 linked evidence item
observation
observed_in
A retrospective analysis reported that individuals taking Rejuvant for an average of 7 months showed a large reduction in DNA methylation biological age.
medium confidence - 1 linked evidence item
assumption
assumes
DNA methylation biological age is a valid surrogate biomarker for healthspan-relevant aging biology in this intervention context.
medium confidence - 1 linked evidence item
premise
assumes
Systemic inflammation is linked to age-related decline and is therefore a plausible mechanism affecting healthspan.
medium confidence
derivation
implies
If CaAKG-based supplementation improves aging biology, part of the effect may occur through reduced systemic inflammation.
medium confidence
project_implication
requires
The Rejuvant Safety and Biomarker Study can test the anti-inflammatory mechanism by comparing C-reactive protein in treated subjects versus placebo.
high confidence
prediction
predicts
Subjects receiving the CaAKG-based supplement will show reduced C-reactive protein compared with placebo.
high confidence
assumption
assumes
C-reactive protein is an appropriate primary endpoint for detecting systemic anti-inflammatory effects of the intervention.
high confidence
derivation
implies
If the trial finds reduced C-reactive protein alongside acceptable safety markers, this would support anti-inflammatory aging modulation as a plausible effect of CaAKG-based supplementation.
medium confidence
prediction
predicts
Subjects receiving the CaAKG-based supplement will show acceptable blood chemistry profiles.
medium confidence
prediction
predicts
Subjects receiving the CaAKG-based supplement will show acceptable adverse-event profiles.
medium confidence
prediction
predicts
Subjects receiving the CaAKG-based supplement may show parallel changes in DNA methylation biological age.
Kennedy publicly ties himself to Rejuvant as its Chief Science Officer, and company materials say he helped develop Rejuvant LifeTabs and speaks about supplementation, healthspan, longevity, and biological age. That is public alignment with the product program. But the supplied evidence does not show him explicitly backing the narrower anti-inflammatory mechanism, CRP endpoint, or the claim that CaAKG improves aging biology by reducing systemic inflammation.
The public evidence identifies Tom Weldon as Ponce De Leon Health's Executive Chairman and shows him presenting Rejuvant as a product to decrease biological age, with references to clinical study data. It does not show him publicly discussing the specific anti-inflammatory theory, C-reactive protein, or the claim that CaAKG works partly by reducing systemic inflammation.
No public quote, publication, or attributed statement from Francis R appears in the provided evidence. The only record is a company PR Newswire page about Ponce De Leon Health and CaAKG, which supports the company narrative in general but does not show this person personally endorsing, mentioning, or contradicting the anti-inflammatory claim tied to C-reactive protein.
The evidence only places Francis R. Palmer, III in the company org chart as Chief Medical Officer. It does not include any public quote, publication, or statement from him about the anti-inflammatory claim, C-reactive protein endpoint, or CaAKG-based aging modulation theory.
silent
The public records here tie Brian Kennedy to Rejuvant and show him speaking about supplementation, healthspan, longevity, and research supporting Rejuvant LifeTabs. They do not show him publicly claiming that the CaAKG supplement reduces systemic inflammation, lowers C-reactive protein, or works through an anti-inflammatory mechanism. On this specific theory, the evidence provided is silent.
The dossier shows Tom Weldon tied to Ponce de Leon Health as a speaker and company leader, and it includes syndicated news items about Rejuvant. It does not show this person publicly discussing the specific anti-inflammatory claim, C-reactive protein endpoint, or the idea that CaAKG improves aging biology by reducing systemic inflammation.
silent
The public evidence ties Tom Weldon to Rejuvant, CaAKG, and biological age claims, but it does not show him endorsing or even explicitly discussing the specific anti-inflammatory theory: reduced systemic inflammation, C-reactive protein, or CRP as a primary endpoint. On this record, he speaks about CaAKG and age reversal more broadly, then stops there.
The theory can explain the reported methylation-clock shift, but it does not yet explain it better than simpler alternatives. A 42-person retrospective analysis with baseline and follow-up testing can detect a biomarker movement; it cannot show that the formulation caused it or that the movement predicts fewer diseases, slower frailty, or longer survival. The 8-year number is large enough to demand a controlled test, not large enough to settle the biology.
Supporting evidence: The reported observation matches one of the theory's predictions: improved aging biomarkers after use.; The paper reports an average 8-year reduction in DNA methylation biological age after 4 to 10 months of Rejuvant use, with an average treatment period of 7 months.; The evidence context states that most participants showed a decrease in biological age.
Counter evidence: No placebo-controlled comparison is provided in the evidence context.; No downstream healthspan endpoint is reported.; The evidence context itself states that placebo-controlled and longer-duration studies are required to test whether the biomarker changes are causal and clinically meaningful.
Falsifiability7.0
The theory is testable. It predicts improved aging biomarkers, repeated-use safety, and later healthspan signals in controlled studies. A randomized placebo-controlled trial could break the claim cleanly: no biomarker difference, worse tolerability, no dose-response, or no healthspan signal after longer follow-up would all count against it. The main fuzziness is that biological aging is a broad endpoint, so the theory needs prespecified clocks, timepoints, and clinical endpoints to avoid moving the goalposts.
Supporting evidence: The theory predicts improved aging biomarkers compared with baseline or controls.; The theory predicts favorable safety and tolerability over repeated use.; The theory predicts downstream evidence consistent with improved healthspan in longer controlled studies.
Counter evidence: The current evidence centers on a biomarker proxy rather than a hard clinical endpoint.; The theory does not specify which DNA methylation clocks, effect size thresholds, or healthspan outcomes would count as failure.; Without prespecified endpoints, a null result on one biomarker could be reinterpreted as the wrong clock rather than a failed theory.
Reasoning tree
premise
Rejuvant is framed as a potential life-extending compound formulation built around alpha-ketoglutarate plus vitamins.
high confidence - 1 linked evidence item
assumption
assumes
A formulation combining alpha-ketoglutarate with vitamins can affect biological aging pathways rather than only treating a single downstream disease.
medium confidence - 1 linked evidence item
derivation
implies
If the formulation delays or reverses biological aging processes, it should plausibly extend healthspan and possibly lifespan.
medium confidence - 1 linked evidence item
observation
observed_in
A retrospective analysis reported that 42 individuals taking Rejuvant for an average of 7 months showed an average 8-year reduction in DNA methylation biological age.
high confidence - 1 linked evidence item
assumption
requires
DNA methylation clock changes are a meaningful biomarker proxy for changes in biological aging relevant to healthspan or lifespan.
medium confidence - 1 linked evidence item
assumption
requires
Placebo-controlled and longer-duration studies are required to determine whether the reported biomarker changes are causal and clinically meaningful.
high confidence - 1 linked evidence item
project_implication
implies
Rejuvant is an intriguing candidate intervention for human aging, but its life- and healthspan claims remain provisional until validated in controlled studies.
high confidence - 1 linked evidence item
prediction
predicts
Treated individuals should show improved aging biomarkers compared with baseline or controls.
high confidence - 1 linked evidence item
prediction
predicts
Treated individuals should show favorable safety and tolerability over repeated use.
medium confidence
prediction
predicts
Longer controlled studies should show downstream evidence consistent with improved healthspan.
Kennedy appears to publicly endorse the theory. The strongest evidence is his public commercial role as Rejuvant/Ponce de Leon Health's Chief Science Officer, plus company material saying he helped develop Rejuvant LifeTabs and would speak about supplementation, healthspan, longevity, and research supporting the product. That is stronger than a passing mention, even if the supplied evidence does not include a direct quote from him personally restating the full CaAKG lifespan theory.
Tom Weldon is identified in the record as Ponce De Leon Health's Founder, Executive Chairman and Acting CEO, and the talk summary says he publicly presented Rejuvant as a supplement developed to decrease biological age in humans, citing clinical-study data for efficacy. That is a direct public endorsement of the company's CaAKG-based healthy-aging theory, not mere mention.
No public statement from Francis R appears in the provided evidence. The only record is a PR Newswire page about Ponce de Leon Health and CaAKG-related claims, and it does not attribute any comment, endorsement, or contradiction to this person.
The provided evidence places Francis R. Palmer, III at Ponce De Leon Health as Chief Medical Officer, but it does not show any public statement from him about Rejuvant or its alpha-ketoglutarate-based life- and healthspan theory. The Rejuvant article excerpt states the company claim, not Palmer's own view.
Brian Kennedy is presented publicly as Rejuvant's Chief Science Officer on the company site, and a PR Newswire release says he helped develop Rejuvant LifeTabs and would discuss research supporting it in the context of healthspan and longevity. That is public endorsement of the formulation's anti-aging theory, even though the evidence here comes from company-linked materials rather than a direct quote from Kennedy himself.
The dossier does not contain a direct quote or clearly attributable public statement from this person about the CaAKG and vitamin formulation theory. The records mention Ponce de Leon Health and Tom Weldon, but they do not tie a statement to "The News Contact Professional" with enough precision to call it an endorsement, mention, or contradiction.
publicly endorses
He does more than mention it. Weldon publicly ties Rejuvant’s core ingredient to anti-aging effects, says CaAKG is the main ingredient and that the product works, appears in material about decreasing biologic age, and is presented as a founder whose own biological age improved. That is a direct public endorsement of the company’s life- and healthspan theory, not a neutral reference.
The theory can explain the reported DNA methylation-age drop, but it does not beat simpler explanations yet. A 42-person retrospective result after about 7 months is compatible with a product effect, but also with selection bias, lifestyle changes, regression to the mean, assay variability, or other uncontrolled factors. The data say something happened in a biomarker readout. They do not yet show that CaAKG reversed cellular aging.
Supporting evidence: The reported observation directly matches the theory's expected direction: lower DNA methylation biological age after Rejuvant use.; The average reported change was large, about 8 years, with a stated p-value of 6.538e-12.
Counter evidence: The evidence context itself marks the attribution to Rejuvant rather than confounding factors as a low-confidence assumption.; No placebo group is described in the supplied evidence.; No head-to-head data are supplied against NMN, resveratrol, or rapamycin.; The observation supports a biomarker change more directly than true tissue rejuvenation.
Falsifiability8.0
This theory is easy to test and easy to kill. A randomized placebo-controlled trial could measure DNA methylation age before and after Rejuvant, with prespecified endpoints and a comparator arm. A direct CaAKG-only arm would test whether the proposed critical molecule carries the effect. If Rejuvant fails to move epigenetic or cellular aging markers, or performs no better than placebo, the central claim takes a clean hit.
Supporting evidence: The theory predicts measurable improvements in cellular aging or epigenetic aging markers in controlled tests.; The evidence context calls for placebo-controlled and comparative studies measuring epigenetic and cellular aging endpoints.; The theory makes a comparative prediction against NMN, resveratrol, and rapamycin, which can be tested in matched assays.
Counter evidence: The threshold for success is not fully specified: which clock, what minimum effect size, and what duration would count.; The phrase cellular rejuvenation is broader than DNA methylation age, so failed biomarker movement would not automatically rule out every possible cellular effect.
Reasoning tree
premise
Calcium alpha-ketoglutarate (CaAKG) is proposed as the critical small molecule in Rejuvant responsible for cellular rejuvenation and age-reversal effects.
medium confidence - 1 linked evidence item
premise
assumes
Small molecules such as CaAKG, NMN, resveratrol, and rapamycin are treated as candidate longevity interventions whose effects can be compared in cellular aging assays.
medium confidence
assumption
requires
Changes in cellular or epigenetic aging markers are valid proxies for cellular rejuvenation or biological age reversal.
medium confidence - 1 linked evidence item
observation
observed_in
A retrospective analysis reported that 42 individuals taking Rejuvant for an average of 7 months showed an average 8-year reduction in DNA methylation biological age.
medium confidence - 1 linked evidence item
derivation
implies
If Rejuvant lowers DNA methylation biological age, then CaAKG-based formulations may influence measurable biomarkers of biological aging in humans.
medium confidence - 1 linked evidence item
prediction
predicts
CaAKG-based Rejuvant should produce measurable improvements in cellular aging or epigenetic aging markers in controlled tests.
medium confidence - 1 linked evidence item
project_implication
implies
The theory should be tested with placebo-controlled and comparative studies measuring epigenetic and cellular aging endpoints for Rejuvant and comparator longevity molecules.
high confidence - 1 linked evidence item
prediction
predicts
CaAKG-based Rejuvant should compare favorably with other candidate longevity molecules such as NMN, resveratrol, or rapamycin in assays of cellular aging reversal.
low confidence
assumption
requires
The observed biological-age reduction is attributable to the Rejuvant formulation rather than uncontrolled confounding factors.
Brian K. Kennedy is publicly presented as Chief Science Officer of Rejuvant/Ponce de Leon Health, and company material says he helped develop Rejuvant and would discuss research supporting it. That is stronger than a passing mention: it is an explicit public association with the product and the company’s age-reversal framing, even though the supplied evidence does not include a direct Kennedy quote on CaAKG outperforming other molecules.
Tom Weldon is identified in the 2022 talk record as Ponce De Leon Health's Founder, Executive Chairman and Acting CEO, and the talk summary says he presented Rejuvant as a supplement developed to decrease biological age in humans, citing clinical-study data for its efficacy. That is a public endorsement of the company's age-reversal claim, even though this record does not spell out the full CaAKG cellular-rejuvenation mechanism.
The provided evidence does not show Francis R making any public statement about this theory. The only record is a PR Newswire company news page describing Ponce de Leon Health and CaAKG-related claims, but it does not attribute any endorsement, mention, or contradiction to Francis R.
The record set places Francis R. Palmer, III at Ponce De Leon Health as Chief Medical Officer, but it does not contain any public statement from him about CaAKG, Rejuvant, cellular rejuvenation, or age reversal. The Rejuvant publication excerpt in the evidence names Oleksandr Demidenko, not Palmer. On this evidence, he stays silent.
The public record here ties Brian Kennedy to Rejuvant and Ponce de Leon Health, but it does not show him explicitly endorsing the specific claim that CaAKG can reverse cellular aging. A December 9, 2020 PR Newswire release says he would discuss research supporting Rejuvant and that he helped develop the supplement, and Rejuvant’s About page lists him as Chief Science Officer. That is public association and implied support for the product, but not a clear on-record endorsement of the full theory text.
The dossier gives no direct public statement from The News Contact Professional about the theory. The records provided are company or event materials about Ponce de Leon Health and Tom Weldon, plus reposted Rejuvant claims, but none attribute a view to this person.
publicly endorses
Tom Weldon is publicly tied to the claim, not merely adjacent to it. In the podcast materials, he is presented as discussing the age-reversal potential of small molecules, with calcium alpha-ketoglutarate described as playing a critical role and being compared against NMN, resveratrol, and rapamycin in cellular aging reversal. The quote calling CaAKG Rejuvant's main ingredient and saying the product is science-based and works strengthens that endorsement.
Supporting evidence: The theory predicts reduced inflammatory biomarkers, especially C-reactive protein, which would connect the mechanism to a measurable human endpoint.; The reported Rejuvant observation gives a human aging-biomarker signal after several months of use.
Counter evidence: The supplied Rejuvant study was retrospective and involved 42 individuals, with no placebo arm described in the evidence context.; The observed endpoint was DNA methylation biological age, not inflammatory burden.; No evidence is provided that CRP reduction mediates any change in aging biomarkers or healthspan.
Falsifiability8.0
This is the strongest Popperian feature. The theory makes a clean test: randomize adults to the proprietary CaAKG formulation or placebo, then compare CRP and safety labs. If CRP does not fall versus placebo, or if blood chemistry or adverse events worsen, the anti-inflammatory healthspan claim takes a direct hit. The remaining fuzziness is that healthspan itself is broader than CRP, so the theory should predefine what size of CRP change counts as meaningful.
Supporting evidence: The theory specifies a placebo comparison.; It names C-reactive protein as a key measurable endpoint.; It includes safety predictions for blood chemistry and adverse-event profiles.
Counter evidence: No threshold is given for a clinically meaningful CRP reduction.; Improved healthspan is broader than short-term inflammatory biomarker movement.; The proprietary formulation makes it harder to falsify CaAKG alone, because other ingredients could drive any observed effect.
Reasoning tree
premise
Ponce de Leon Health's proprietary CaAKG-based dietary supplements are framed as potentially anti-inflammatory.
medium confidence
derivation
implies
CaAKG-based supplementation may reduce systemic inflammation.
medium confidence
observation
requires
Systemic inflammation can be operationalized using C-reactive protein as an inflammatory biomarker.
high confidence
derivation
implies
Lowering inflammatory burden is relevant to healthier aging and improved healthspan.
medium confidence
project_implication
implies
CaAKG-based supplementation may improve healthspan through anti-inflammatory effects.
medium confidence
prediction
predicts
Adults receiving the proprietary CaAKG formulation should show improved inflammatory biomarkers versus placebo.
medium confidence
prediction
predicts
Adults receiving the proprietary CaAKG formulation should show reduced C-reactive protein versus placebo.
medium confidence
assumption
assumes
The proprietary CaAKG formulation tested in adults is sufficiently comparable to the CaAKG-based supplementation described in the causal claim.
medium confidence - 1 linked evidence item
prediction
predicts
Adults receiving the proprietary CaAKG formulation should maintain acceptable blood chemistry profiles.
medium confidence
prediction
predicts
Adults receiving the proprietary CaAKG formulation should maintain acceptable adverse-event safety profiles.
medium confidence
observation
observed_in
A retrospective analysis reported that individuals taking Rejuvant, an alpha-ketoglutarate based formulation, showed an average decrease in DNA methylation biological age after several months of use.
medium confidence - 1 linked evidence item
assumption
assumes
Changes in inflammatory biomarkers such as C-reactive protein are meaningful indicators of inflammatory burden relevant to healthspan.
Brian K. Kennedy is publicly tied to Rejuvant and Ponce de Leon Health as Chief Science Officer, and a company release says he helped develop Rejuvant LifeTabs and would discuss supplementation on healthspan. But the supplied evidence does not show him publicly stating the specific claim that CaAKG works through anti-inflammatory effects or reduces C-reactive protein. On this theory, he is publicly silent.
Tom Weldon is publicly identified as Ponce De Leon Health's Executive Chairman, and in a 2022 talk he publicly introduced Rejuvant and cited clinical-study data to support its efficacy. That is a public discussion of the product behind the theory, but the evidence here does not show him explicitly endorsing the specific anti-inflammatory mechanism or the CRP prediction.
The provided evidence does not contain any public quote, publication, or attributed statement from Francis R about CaAKG supplementation, inflammation, C-reactive protein, or the Rejuvant study. The PR Newswire company news page mentions Ponce de Leon Health and CaAKG-related press coverage, but it does not show Francis R endorsing, discussing, or disputing this theory.
The evidence does not show any public statement from Francis R. Palmer about CaAKG, inflammation, C-reactive protein, or the Rejuvant Safety and Biomarker Study. One record lists him as Chief Medical Officer at Ponce De Leon Health, and another discusses Rejuvant's formulation, but neither attributes a view or quote to him.
The record shows Brian Kennedy publicly tied to Rejuvant and Ponce de Leon Health: a 2020 PRNewswire release says he would discuss supplementation on healthspan and research supporting Rejuvant LifeTabs, and Rejuvant's site lists him as Chief Science Officer. That is public association and product-level support. It does not specifically show him endorsing the narrower anti-inflammatory and CRP claim in the theory.
The provided evidence does not show any public statement from The News Contact Professional about the CaAKG anti-inflammatory theory. The records mention Ponce de Leon Health, Rejuvant, and Tom Weldon, but none attribute an endorsement, neutral mention, or contradiction of the CRP or inflammation claim to this person.
mentions
Tom Weldon publicly promotes CaAKG as Rejuvant's main ingredient, says the product is clinically proven and works, and is described discussing CaAKG's role in healthier aging. That is a public mention of the broader CaAKG and healthspan thesis. The evidence here does not show him specifically endorsing the anti-inflammatory mechanism, C-reactive protein reduction, or the exact causal chain in the theory.
Supporting evidence: The theory predicts improved aging biomarkers after a successful non-drug longevity intervention.; The cited Rejuvant analysis reported a large average DNA methylation age reduction after treatment.
Counter evidence: The study was retrospective, with 42 participants and no untreated control group in the supplied abstract.; The evidence does not connect methylation clock change to fewer diagnoses, slower functional decline, or lower mortality.
Falsifiability8.0
This theory is testable. It predicts that a successful product should improve aging biomarkers versus untreated controls, and later reduce functional decline or degenerative disease burden versus controls. Those claims can fail in a randomized trial if methylation clocks do not move, if function does not improve, or if disease rates stay the same despite biomarker change.
Supporting evidence: The theory gives a near-term prediction: biomarkers of aging should improve compared with untreated controls.; The theory gives a longer-term prediction: age-related functional decline or degenerative disease burden should fall compared with untreated controls.
Counter evidence: The theory still uses broad terms such as moderate, slow, or reverse aging biology, so trial endpoints need prespecified clock types, effect sizes, follow-up duration, and disease outcomes.; A biomarker-only study could leave the strongest disease-risk claim unresolved.
Reasoning tree
premise
Biological aging is a causal upstream driver of degenerative disease risk.
medium confidence
derivation
implies
If biological aging causally contributes to degenerative disease, then targeting aging biology could reduce downstream disease risk.
medium confidence
assumption
requires
Aging biology can be meaningfully moderated, slowed, or reversed in humans by interventions.
medium confidence - 1 linked evidence item
assumption
assumes
Biomarkers of aging, such as DNA methylation clocks, are valid enough intermediate indicators to evaluate whether an intervention affects biological aging.
medium confidence - 1 linked evidence item
derivation
implies
Interventions that improve aging biomarkers may plausibly improve healthspan and potentially lifespan if those biomarkers reflect causal aging processes.
medium confidence - 1 linked evidence item
observation
observed_in
A retrospective analysis of 42 people taking an alpha-ketoglutarate formulation reported an average reduction in DNA methylation biological age after about seven months.
medium confidence - 1 linked evidence item
project_implication
implies
A non-drug longevity product should be designed to safely and affordably target aging biology rather than only treating established disease.
medium confidence
prediction
predicts
A successful non-drug longevity product should improve biomarkers of aging compared with untreated controls.
high confidence - 1 linked evidence item
prediction
predicts
Over longer follow-up, a successful non-drug longevity product should reduce age-related functional decline or degenerative disease burden compared with untreated controls.
medium confidence
assumption
assumes
Short-term improvements in aging biomarkers will translate into longer-term reductions in functional decline or disease burden.
Kennedy publicly aligns with the core theory. The clearest signal is the 2019 statement tying aging to many diseases: "The one risk factor shared by a bevy of diseases? Aging." That is the upstream-causation claim in plain form. He also publicly served as Chief Science Officer for Rejuvant/Ponce de Leon Health, and company material linked him to discussing supplementation, healthspan, and tracking biological-age markers for Rejuvant LifeTabs. This goes past a stray mention and reads as active public support for the company’s aging-focused thesis.
Tom Weldon publicly backs the theory. In his 2022 talk, titled "Decreasing biological age for all," he presents Rejuvant as a supplement developed to decrease biological age in humans and says he is using clinical study data to support its efficacy. That is a direct public endorsement of the idea that modifying aging biology can improve health outcomes.
The record supports the company's aging-focused theory, but it does not show any public statement from Francis R. There are no quotes or publications tied to this person, so we cannot attribute endorsement, mention, or contradiction to him from the evidence provided.
The evidence links Francis R. Palmer, III to the company as Chief Medical Officer, but it does not show any public statement from him about the theory. The other record discusses a Rejuvant formulation and biological aging, yet the excerpt does not attribute that claim to Palmer. On this record, he stays silent.
Brian Kennedy is presented publicly as helping develop Rejuvant for Ponce de Leon Health and discussing supplementation's impact on healthspan, longevity, and biological age tracking. That is a direct public alignment with the theory that aging biology can be modified with a non-drug intervention to improve later-life health.
The dossier provides no direct quote, statement, or attributed publication from The News Contact Professional about this theory. The records mention Ponce de Leon Health and, in one case, Tom Weldon speaking on 'decreasing biologic age for all,' but that is not evidence that this specific person publicly endorses or contradicts the claim.
publicly endorses
Tom Weldon publicly endorses the theory. The strongest evidence is Ponce de Leon Health's public claim that it seeks to "reverse the effects of biological aging" and help "moderate the number one cause of degenerative diseases, aging," plus repeated public promotion of healthspan, lifespan, biological age, and age reversal in materials tied to Weldon as founder or CEO.
Supporting evidence: The observed outcome matches the theory's predicted direction: methylation age decreased after supplementation.; The publication reported a statistically significant average change in DNA methylation age.
Counter evidence: The evidence node explicitly says the reported reduction could reflect selection bias, placebo effects, regression to the mean, measurement variability, or uncontrolled confounding.; No cited controlled prospective trial shows that CaAKG causes methylation-pattern change or functional tissue rejuvenation.
Falsifiability8.0
This theory is quite falsifiable. A placebo-controlled prospective trial can pre-specify DNA methylation clocks, cellular-aging readouts, dosing, duration, and comparator molecules. If CaAKG does not produce a reproducible methylation-age reduction, or performs no better than placebo on the chosen clocks, the central prediction takes a direct hit.
Supporting evidence: The theory predicts measurable methylation-pattern changes associated with biological-age reduction.; The evidence context proposes a direct test: compare CaAKG-based supplementation against placebo and other longevity molecules using pre-specified DNA methylation clocks and cellular-aging readouts.
Counter evidence: The phrase 'related small molecules' broadens the claim and could let failed CaAKG results be shifted onto other compounds unless the intervention is defined before testing.; Epigenetic clocks vary, so the theory needs pre-specified clocks to avoid cherry-picking favorable readouts.
Reasoning tree
premise
Calcium alpha-ketoglutarate and related small molecules are proposed as non-drug interventions capable of reversing cellular aging and promoting rejuvenation of cells and tissues through epigenetic reversal.
medium confidence
assumption
assumes
Aging-associated DNA methylation patterns are causally linked to cellular aging state rather than merely correlated with it.
medium confidence - 1 linked evidence item
derivation
implies
If CaAKG can alter aging-associated methylation patterns toward a younger profile, then it may reduce measured biological age on epigenetic-aging clocks.
medium confidence - 1 linked evidence item
prediction
predicts
CaAKG-based supplementation should produce measurable methylation-pattern changes associated with biological-age reduction.
high confidence - 1 linked evidence item
observation
observed_in
A retrospective analysis of 42 individuals taking an alpha-ketoglutarate-based formulation reported an average DNA methylation age decrease of about 8 years after roughly 7 months of supplementation.
medium confidence - 1 linked evidence item
assumption
requires
The reported DNA methylation age reduction reflects a true intervention effect rather than selection bias, placebo effects, regression to the mean, measurement variability, or uncontrolled confounding.
low confidence - 1 linked evidence item
derivation
implies
Because the available human evidence cited is retrospective and not placebo-controlled, the rejuvenation claim requires confirmation in controlled prospective trials.
high confidence - 1 linked evidence item
project_implication
requires
A useful evaluation project would compare CaAKG-based supplementation against placebo and other longevity molecules using pre-specified DNA methylation clocks and cellular-aging readouts.
high confidence - 1 linked evidence item
prediction
predicts
CaAKG-based supplementation should outperform or compare favorably with other longevity molecules on cellular aging or epigenetic-aging readouts.
Public company materials identify Brian K. Kennedy as Chief Science Officer of Rejuvant/Ponce de Leon Health, and a company press release says he helped develop Rejuvant LifeTabs while describing Ponce as focused on reversal of epigenetic aging. That is public alignment with the company’s small-molecule epigenetic rejuvenation theory, though the supplied evidence is indirect rather than a direct personal quote from Kennedy endorsing the mechanism.
Tom Weldon is identified as Ponce De Leon Health's Founder, Executive Chairman, and Acting CEO, and in a public 2022 talk he presents Rejuvant as a company-developed supplement intended to 'decrease biological age in humans' and cites clinical-study efficacy. That is a public endorsement of the company's rejuvenation/small-molecule anti-aging thesis, even though the provided evidence does not explicitly spell out epigenetic reversal or CaAKG methylation mechanisms.
The provided evidence contains only a company PR/news page describing Ponce De Leon Health and CaAKG-related claims; it does not contain any public statement, quote, publication, or attributed remark from Francis R. On the supplied record, there is no person-specific endorsement, mention, or contradiction.
The provided evidence does not show any public statement, quote, or authored publication by Francis R. Palmer about the theory. One record only lists him as Chief Medical Officer in an org chart, and the cited Rejuvant publication is not attributed to him.
Public records tie Brian Kennedy, Ph.D. directly to the company and product: the PRNewswire release says he would discuss research supporting Rejuvant LifeTabs and that he helped develop the supplement brand for Ponce de Leon Health; the company About page lists him as Chief Science Officer. That is stronger than a mere mention and is consistent with a public endorsement of the company’s small-molecule rejuvenation framing.
No provided quote or record shows The News Contact Professional making a public statement about small-molecule epigenetic rejuvenation, CaAKG, or related methylation-age reversal claims. The records mention Ponce de Leon Health and Tom Weldon, but not this person endorsing, discussing, or disputing the theory.
publicly endorses
Tom Weldon is publicly tied to Rejuvant/Ponce de Leon Health as founder/CEO, and public interview records describe him discussing the transformative potential of small molecules, the critical role of calcium alpha-ketoglutarate, reversal of cellular aging, rejuvenation of cells and tissues, and epigenetic reversal. That goes beyond a passing mention and aligns with the theory’s core claim.
Supporting evidence: The observed Rejuvant result points in the broad direction of altered aging biomarkers after supplementation.; The project implication correctly calls for inflammatory biomarkers to be measured alongside safety labs and adverse events.
Counter evidence: The main cited observation is retrospective and non-placebo-controlled.; The observed endpoint is DNA methylation age, while the causal theory centers on inflammation and C-reactive protein.; No controlled prospective evidence is provided linking CaAKG supplementation to reduced inflammatory biomarkers.
Falsifiability8.0
This theory is easy to test and easy to wound. Randomize adults to CaAKG-based supplement or placebo, measure C-reactive protein and other inflammatory markers before and after treatment, and track safety labs and adverse events. If C-reactive protein does not improve versus placebo, or safety labs move in the wrong direction, the stated prediction takes a direct hit.
Supporting evidence: The prediction specifies favorable changes in inflammatory biomarkers, especially C-reactive protein.; The theory also predicts acceptable safety laboratory values and adverse-event profiles.; The evidence context says a stronger test would require controlled prospective evidence.
Counter evidence: The theory does not define the required effect size, treatment duration, population, or threshold for an acceptable safety profile.; Healthspan biology remains broader than C-reactive protein, so a negative biomarker result may still leave room for weaker fallback claims.
Reasoning tree
premise
Proprietary CaAKG-based dietary supplements are framed as having anti-inflammatory properties relevant to healthspan biology.
medium confidence - 1 linked evidence item
assumption
assumes
Chronic inflammation contributes causally to aging-related biological processes and age-related decline.
medium confidence
assumption
assumes
C-reactive protein is an appropriate biomarker for tracking chronic inflammation in adults receiving the supplement.
medium confidence
derivation
implies
If CaAKG-based supplementation reduces chronic inflammation, it may moderate biological processes linked to aging and age-related decline.
medium confidence - 1 linked evidence item
prediction
predicts
Adults receiving the CaAKG-based supplement should show favorable changes in inflammatory biomarkers, especially C-reactive protein.
medium confidence
project_implication
requires
The Rejuvant safety and biomarker program should evaluate inflammatory biomarker changes alongside safety labs and adverse events to test whether CaAKG supplementation improves healthspan biology through anti-inflammatory effects.
high confidence
project_implication
requires
A stronger test of the theory would require controlled prospective evidence linking CaAKG supplementation to reduced inflammatory biomarkers and acceptable safety outcomes.
high confidence - 1 linked evidence item
prediction
predicts
Adults receiving the CaAKG-based supplement should maintain acceptable safety laboratory values and adverse-event profiles.
medium confidence
observation
observed_in
A retrospective analysis of 42 individuals taking Rejuvant, an alpha-ketoglutarate-based formulation, reported an average decrease in DNA methylation biological age after about 7 months of use.
medium confidence - 1 linked evidence item
assumption
assumes
DNA methylation biological age changes are relevant evidence for healthspan or aging biology effects of CaAKG-based supplementation.
medium confidence - 1 linked evidence item
assumption
requires
Evidence from a retrospective, non-placebo-controlled Rejuvant analysis can support but cannot by itself establish the anti-inflammatory causal mechanism.
Kennedy is publicly presented by Rejuvant/Ponce de Leon Health as its Chief Science Officer, and a company press release says he would discuss supplementation’s role in healthspan and research supporting Rejuvant LifeTabs. That is public promotional alignment with the supplement program, which supports an endorsement classification, even though the supplied evidence does not directly quote him on the specific anti-inflammatory/CRP mechanism.
The identified person appears to be Tom Weldon, who publicly discusses Rejuvant and its claimed efficacy in decreasing biological age, but the provided evidence does not show him addressing the specific anti-inflammatory CaAKG theory, inflammatory biomarkers such as C-reactive protein, or a related causal mechanism.
The provided evidence contains no attributed quote, publication, or statement from Francis R about CaAKG, inflammation, CRP, or the related healthspan theory. The only record is a company PR/news listing, which is not a public statement by this person.
The provided evidence only places Francis R. Palmer, III in the company org chart as Chief Medical Officer. It does not include any public quote, publication authorship, or attributed statement from Palmer endorsing, discussing, or disputing the anti-inflammatory CaAKG/CRP theory.
The provided records link Brian Kennedy, Ph.D. to Rejuvant and supplementation research, but none of the evidence publicly addresses the specific anti-inflammatory CaAKG theory, inflammatory biomarkers such as C-reactive protein, or a contradiction of that claim.
silent
The provided evidence records discuss Ponce de Leon Health/Rejuvant generally and one named executive, Tom Weldon, but do not show any public statement, quote, or attributed commentary from The News Contact Professional about the anti-inflammatory CaAKG theory.
mentions
Tom Weldon is publicly tied to Rejuvant/Ponce de Leon Health and discusses CaAKG as the company’s main, clinically studied ingredient for healthspan and aging-related benefits, but the provided evidence does not show him explicitly endorsing the specific anti-inflammatory mechanism or biomarker prediction (for example CRP improvement).
